Formulation Development
SGS Designated as a Notified Body Under EU IVDR
SGS, the world’s leading testing, inspection and certification company, is delighted to announce the designation of SGS Belgium NV as a Notified Body (NB) under…
PCI Pharma Services to Acquire US-Based Aseptic Fill-Finish CDMO Ajinomoto Althea
PCI Pharma Services is acquiring an entire equity stake in Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co.,…
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients With Cyclin E1+ PROC
Zentalis Pharmaceuticals, Inc. recently announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in…
Purple Biotech Reports Positive NT219 Data for Colorectal & Head & Neck Cancers
Purple Biotech Ltd. recently announced two posters reporting new NT219 data presented at the American Association for Cancer Research (AACR 2025) Annual Meeting on Sunday…
Artelo Biosciences Announces New Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
Artelo Biosciences, Inc. recently announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo…
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA From Pretargeted RIT Platform
Y-mAbs Therapeutics, Inc. recently announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of…
Polyrizon Reports Successful Safety Study of a Formulation of Allergy Blocker in Human Nasal Tissue Model
Polyrizon Ltd. recently announced the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product’s development…
Avidicure Launches With $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer
Avidicure recently announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM,…
BriaCell Confirms 100% Resolution of Lung Metastasis With Bria-OTS
BriaCell Therapeutics Corp. confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing…
Inmagene Reports Topline Results From Phase 2a Study of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life in Patients With Alopecia Areata
Inmagene Biopharmaceuticals recently reports topline results from the Phase 2a trial of IMG-007 in patients with severe alopecia areata (AA). “AA is an I&I disease…
Facility Update From Sever Pharma Solutions
In 2024, our Putnam site fully commissioned and qualified two new High Potent API processing suites, one for development and one for GMP manufacturing. These…
Cytovation Raises $6M to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts
Cytovation ASA recently announced it has raised NOK62 million (US$6m) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101…
Boehringer Ingelheim & Tessellate Bio Partner to Develop First-in-Class Precision Treatments for People With Hard-to-Treat Cancers
Boehringer Ingelheim and Tessellate Bio have entered into a research collaboration and global license agreement. Jointly the partners will focus on the development of first-in-class,…
BPGbio Presents New Research on Tumor Metabolism, Immunotherapy & Diagnostics
BPGbio, Inc. recently announced the presentation of seven presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in…
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences, Ltd. recently announced dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients…
Bluejay Therapeutics Announces Upcoming Presentation of Preclinical Data in Metabolic Dysfunction-Associated Steatohepatitis
Bluejay Therapeutics recently announced it will present new preclinical data on the characterization of BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor being investigated for the…
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of First-in-Class Oral STAT6 Degrader
Kymera Therapeutics, Inc. recently announced it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of…
March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
March Biosciences recently announced the first patient has been dosed in its Phase 2 clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for…
Ocean Biomedical Expands Into Energy & Digital Asset Sectors to Accelerate Growth & Shareholder Value
Ocean Biomedical, Inc. recently announced a strategic expansion of its business operations to include power infrastructure development and a cryptocurrency treasury strategy, including Bitcoin and Solana. This move comes…
Kindeva Bolsters Executive Team With Chief Quality Officer
Kindeva recently announced the appointment of Melanie Cerullo as Chief Quality Officer to drive its quality, compliance and regulatory strategy. With a proven track record in…
